The Cooper Companies is expected to report Q3 2026 revenue of $1.12 billion and adjusted EPS of $1.11, while the current stock price of $108.42 trades below the average analyst target of $124.50. The primary story for investors is the organic revenue growth within the CooperVision segment, which serves as the company's main valuation driver.
Market participants are looking for continued adoption of the MiSight myopia management portfolio and stable performance in the CooperSurgical fertility business. Analysts are also monitoring whether the company can maintain its margin expansion trajectory amid a competitive contact lens market and shifting global economic conditions.